Presentation is loading. Please wait.

Presentation is loading. Please wait.

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients  Hideki Endoh, MD, PhD,

Published byBaldwin Richard Modified over 5 years ago

Similar presentations

Presentation on theme: "PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients  Hideki Endoh, MD, PhD,"— Presentation transcript:

1 PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients  Hideki Endoh, MD, PhD, Yasushi Yatabe, MD, PhD, Takayuki Kosaka, MD, Hiroyuki Kuwano, MD, PhD, Tetsuya Mitsudomi, MD, PhD  Journal of Thoracic Oncology  Volume 1, Issue 7, Pages (September 2006) DOI: /S (15) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Effect of EGFR mutations (A) and KRAS mutations (B) on survival of patients who received gefitinib treatment. Journal of Thoracic Oncology 2006 1, DOI: ( /S (15) ) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Effect of expression of EGFR (A), PIK3CA (B), and PTEN (C) gene expression status on survival of patients who received gefitinib treatment. Cutoff values of expression were median (i.e., for EGFR, for PIK3CA, and for PTEN). Journal of Thoracic Oncology 2006 1, DOI: ( /S (15) ) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Combined effect of EGFR mutation and PIK3CA expression (A) or EGFR mutation and PTEN expression (B) on survival of patients who received gefitinib treatment. Journal of Thoracic Oncology 2006 1, DOI: ( /S (15) ) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients  Hideki Endoh, MD, PhD,"

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas  Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,

Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas  Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,
Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer  Suzanne Jenkins, DPhil, James C-H.

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer  Suzanne Jenkins, DPhil, James C-H.
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non– Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI  Akito Hata,

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non– Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI  Akito Hata,
Frank Detterbeck, MD  Journal of Thoracic Oncology 

Frank Detterbeck, MD  Journal of Thoracic Oncology 

Similar presentations

Ads by Google